{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:48:26Z","timestamp":1791881306599,"version":"4.3.4"},"reference-count":32,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2026,9,19]]},"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1136\/bmjresp-2026-004324","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:30:15Z","timestamp":1791606615000},"page":"e004324","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Protocol and rationale for a randomised, double-blind, placebo-controlled phase 3 trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic pulmonary fibrosis: ALOFT-IPF"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct06003426","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04308681","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06003426","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06025578","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06003426","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04308681","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-9149","authenticated-orcid":false,"given":"Toby M","family":"Maher","sequence":"first","affiliation":[{"name":"Keck School of Medicine of USC, University of Southern California, Los Angeles, California, USA"},{"name":"National Heart and Lung Institute, Imperial College, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-3182","authenticated-orcid":false,"given":"Fernando","family":"Martinez","sequence":"additional","affiliation":[{"name":"University of Massachusetts Chan Medical School\/UMass Memorial Health System, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[{"name":"Lung Center Mainz, University Medical Center, Mainz and Marienhaus Clinic Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamera J","family":"Corte","sequence":"additional","affiliation":[{"name":"Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia"},{"name":"University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Wijsenbeek","sequence":"additional","affiliation":[{"name":"Center of Expertise for Interstitial Lung Disease and Sarcoidosis, Erasmus MC, University Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[{"name":"Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[{"name":"Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuojun","family":"Xu","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryeh","family":"Fischer","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cerullo","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Elsharkawi","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Patel","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[{"name":"National French Reference Coordinating Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, ERN-LUNG, UMR 754, INRAE, University Claude Bernard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"2026101301050504000_13.1.e004324.1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101301050504000_13.1.e004324.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2005230"},{"key":"2026101301050504000_13.1.e004324.3","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2024.3669"},{"key":"2026101301050504000_13.1.e004324.4","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.2.ats3-00"},{"key":"2026101301050504000_13.1.e004324.5","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.2.ats01"},{"key":"2026101301050504000_13.1.e004324.6","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00170-2018","article-title":"Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry","volume":"5","author":"Kaunisto","year":"2019","journal-title":"ERJ Open Res"},{"key":"2026101301050504000_13.1.e004324.7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02420-2017","article-title":"The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?","volume":"51","author":"Ryerson","year":"2018","journal-title":"Eur Respir J"},{"key":"2026101301050504000_13.1.e004324.8","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0693-1"},{"key":"2026101301050504000_13.1.e004324.9","unstructured":"OFEV (nintedanib capsules) [package insert]. Ridgefield, CT, USA; Boehringer Ingelheim Pharmaceuticals; 2024."},{"key":"2026101301050504000_13.1.e004324.10","unstructured":"ESBRIET (pirfenidone) [package insert]. South San Francisco, CA, USA; Genentech USA; 2023."},{"key":"2026101301050504000_13.1.e004324.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2026101301050504000_13.1.e004324.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2026101301050504000_13.1.e004324.13","doi-asserted-by":"crossref","first-page":"102261","DOI":"10.1016\/j.pupt.2023.102261","article-title":"The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting","volume":"83","author":"Santos","year":"2023","journal-title":"Pulm Pharmacol Ther"},{"key":"2026101301050504000_13.1.e004324.14","unstructured":"JASCAYD (nerandomilast tablets) [package insert]. Ridgefield, CT, USA; Boehringer Ingelheim Pharmaceuticals; 2025."},{"key":"2026101301050504000_13.1.e004324.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414108"},{"key":"2026101301050504000_13.1.e004324.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01158-9"},{"key":"2026101301050504000_13.1.e004324.17","unstructured":"United Therapeutics Corporation . United Therapeutics Corporation announces TETON-2 pivotal study of Tyvaso\u00ae meets primary endpoint for the treatment of idiopathic pulmonary fibrosis. 2025. Available: https:\/\/ir.unither.com\/~\/media\/Files\/U\/United-Therapeutics-IR\/documents\/press-releases\/2025\/teton-2-press-release.pdf [Accessed 23 Sep 2025]."},{"key":"2026101301050504000_13.1.e004324.18","article-title":"TETON phase 3 clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis","volume":"66","author":"Nathan","year":"2025","journal-title":"Eur Respir J"},{"key":"2026101301050504000_13.1.e004324.19","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201403-0509PP"},{"key":"2026101301050504000_13.1.e004324.20","doi-asserted-by":"publisher","DOI":"10.1096\/fj.12-219378"},{"key":"2026101301050504000_13.1.e004324.21","doi-asserted-by":"publisher","DOI":"10.1038\/nm1685"},{"key":"2026101301050504000_13.1.e004324.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.09.081"},{"key":"2026101301050504000_13.1.e004324.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2021-001026","article-title":"Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)","volume":"8","author":"Corte","year":"2021","journal-title":"BMJ Open Respir Res"},{"key":"2026101301050504000_13.1.e004324.24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1164\/rccm.202405-0977OC","article-title":"Efficacy and safety of admilparant, an LPA1 antagonist, in pulmonary fibrosis: a phase 2 randomized clinical trial","volume":"211","author":"Corte","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101301050504000_13.1.e004324.25","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3495"},{"key":"2026101301050504000_13.1.e004324.26","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.201000239"},{"key":"2026101301050504000_13.1.e004324.27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp2513633","article-title":"Statistics in medicine - what\u2019s in an estimand?","volume":"394","author":"Troxel","year":"2026","journal-title":"N Engl J Med"},{"key":"2026101301050504000_13.1.e004324.28","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202312-2213SO"},{"key":"2026101301050504000_13.1.e004324.29","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1164\/rccm.202401-0116OC","article-title":"Zinpentraxin alfa for idiopathic pulmonary fibrosis: the randomized phase III STARSCAPE trial","volume":"209","author":"Richeldi","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101301050504000_13.1.e004324.30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001310","article-title":"Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis","volume":"9","author":"Nathan","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"2026101301050504000_13.1.e004324.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001563","article-title":"Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)","volume":"10","author":"Richeldi","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"2026101301050504000_13.1.e004324.32","unstructured":"European Medicines Agency . Concept paper on new guidance on the clinical investigation of medicinal products for the treatment of idiopathic pulmonary fibrosis (IPF). EMA\/CHMP\/290364\/2025. 2025."}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2026-004324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:05:19Z","timestamp":1791878719000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2026-004324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,10,9]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bmjresp-2026-004324"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2026-004324","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}